Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.

Didoni A, Sequi M, Panei P, Bonati M; Lombardy ADHD Registry Group.

Eur J Clin Pharmacol. 2011 Oct;67(10):1061-7. doi: 10.1007/s00228-011-1050-3. Epub 2011 May 3.

PMID:
21538145
2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
4.

Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.

Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P.

CNS Drugs. 2015;29(10):865-77. doi: 10.1007/s40263-015-0266-7.

PMID:
26293742
5.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
6.

Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.

Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, Rossi F, Capuano A.

J Child Adolesc Psychopharmacol. 2012 Dec;22(6):415-22. doi: 10.1089/cap.2012.0003.

PMID:
23234585
7.

Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.

Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P; Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.

J Child Adolesc Psychopharmacol. 2012 Dec;22(6):423-431.

PMID:
23362511
8.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. Epub 2013 Apr 6. Review.

9.

Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.

Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B.

Child Psychiatry Hum Dev. 2011 Jun;42(3):257-69. doi: 10.1007/s10578-010-0212-3.

PMID:
21165694
10.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

11.

Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.

Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.

Eur Neuropsychopharmacol. 2014 Dec;24(12):1873-84. doi: 10.1016/j.euroneuro.2014.09.013. Epub 2014 Oct 18.

PMID:
25453480
12.

An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):485-92. doi: 10.1089/cap.2008.0125.

13.

Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.

Capuano A, Scavone C, Rafaniello C, Arcieri R, Rossi F, Panei P.

Expert Opin Drug Saf. 2014 Sep;13 Suppl 1:S69-78. doi: 10.1517/14740338.2014.941804.

PMID:
25171160
14.

Effects of atomoxetine and methylphenidate on sleep in children with ADHD.

Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D.

Sleep. 2006 Dec;29(12):1573-85.

PMID:
17252888
15.
16.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
17.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

18.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
19.
20.

Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.

Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R.

J Clin Psychopharmacol. 2013 Dec;33(6):766-74. doi: 10.1097/JCP.0b013e31829c762b.

PMID:
23963057

Supplemental Content

Support Center